Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative (NQ:XOMAO)

25.47 -0.07 (-0.28%)
Streaming Delayed Price Updated: 3:16 PM EDT, Sep 12, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 359
Open 25.47
Bid (Size) 25.30 (1)
Ask (Size) 25.68 (1)
Prev. Close 25.54
Today's Range 25.47 - 25.47
52wk Range 23.32 - 25.87
Shares Outstanding N/A
Dividend Yield 8.21%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
From XOMA Royalty Corporation
Via GlobeNewswire
Mural Oncology Announces Entry into Agreement to be Acquired by XRA 5 Corp., a wholly owned subsidiary of XOMA Royalty for between $2.035 and $2.24 in Cash per Share
From XOMA Royalty Corporation
Via GlobeNewswire

Performance

YTD
-0.6%
-0.6%
1 Month
+0.0%
+0.0%
3 Month
+0.5%
+0.5%
6 Month
+0.2%
+0.2%
1 Year
+1.1%
+1.1%

More News

Read More
XOMA Royalty Reports Second Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Announces Closing of Tender Offer for Turnstone Biologics
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Enters into Agreement to Acquire LAVA Therapeutics for Between $1.16 and $1.24 Per Share in Cash, Plus a Contingent Value Right
From XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via GlobeNewswire
HilleVax Enters into a Definitive Agreement to be Acquired by XOMA Royalty for $1.95 in Cash per Share Plus a Contingent Value Right
From XOMA Royalty Corporation
Via GlobeNewswire
Turnstone Biologics Corp. Enters into Agreement to be Acquired by XOMA Royalty Corporation for $0.34 in Cash Per Share Plus a Contingent Value Right
From XOMA Royalty Corporation; Turnstone Biologics Corp.
Via GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Purchases Mezagitamab Royalty and Milestone Rights Held by BioInvent International for up to USD $30 Million
From XOMA Royalty Corporation; BioInvent
Via GlobeNewswire
XOMA Royalty Reports First Quarter 2025 Financial Results and Highlights Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty to Present at H.C. Wainwright 1st Annual Royalty Company Virtual Conference
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Completes Sale of Kinnate Pipeline Assets
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty to Present at Jones Healthcare and Technology Innovation Conference
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Business Achievements
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty to Present at Investor Conferences in March
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Royalty Corporation
Via GlobeNewswire
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
From XOMA Corporation
Via GlobeNewswire
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty to Present at Upcoming Investor Conferences in September
From XOMA Corporation
Via GlobeNewswire
XOMA Royalty Reports Second Quarter 2024 Financial Results and Highlights Recent Activities
From XOMA Corporation
Via GlobeNewswire

Frequently Asked Questions

Is XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative publicly traded?
Yes, XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is publicly traded.
What exchange does XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trade on?
XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative trades on the Nasdaq Stock Market
What is the ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?
The ticker symbol for XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is XOMAO on the Nasdaq Stock Market
What is the current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative?
The current price of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative is 25.47
When was XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative last traded?
The last trade of XOMA Royalty Corporation - Depositary Shares Rep Series B 8.375% Cumulative was at 09/12/25 03:16 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.